Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Cred. LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +$0.0025 +0.22% $1.1175 $1.1125 $1.12 $1.1225 $1.12 $1.12 27,859 16:35:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown - - - - 588.64

Biopharma Cred. Share Discussion Threads

Showing 1 to 4 of 25 messages
Chat Pages: 1
DateSubjectAuthorDiscuss
20/6/2017
08:49
Premium to nav now 13%. Factsheet for May: Http://bpcruk.com/wp-content/uploads/2017/02/BioPharma_Credit_PLC-Fact_Sheet-May_2017.pdf Premium maybe explained by IRR on the Depomed loan of 11.9% which won't be booked until repayment. if other assets behave similarly, it might be justified.
jonwig
28/3/2017
07:20
Http://citywire.co.uk/investment-trust-insider/news/biopharma-credit-targets-7-yield-from-healthcare-bonds/a1003411?ref=investment-trust-insider-latest-news-list
jonwig
25/3/2017
07:17
Dealings begin 27 March. "Therefore, the Gross Issue Proceeds total US$761,877,360 and accordingly the Company will issue 761,877,360 Shares. This exceeds the Company's initial target of US$300 million." Rather impressive demand, should see an opening premium. My broker (TDD) wasn't offering it, and sending a USD cheque with proofs of identity was messy, so we'll wait and see. EDIT: bought.
jonwig
25/3/2017
07:11
. HTTP://bpcruk.com/# . ~~~~~~~~~~~~~~~~~~~~~~~~~~~ BioPharma Credit plc provides investors with an opportunity to gain exposure to the fast growing life sciences industry, through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. BioPharma Credit’s primary objective is to generate predictable income for shareholders over the long term. Once substantially invested, BioPharma Credit will target an annual dividend yield of 7 per cent. (calculated by reference to the Issue Price), and a net total return on NAV of 8 to 9 per cent. per annum in the medium term. Pharmakon Advisors, the fund’s Investment Manager, was founded in 2009 and has invested US$1.3 billion in 20 transactions across four funds. The first three funds are now fully invested. Drawing upon the expertise and successful track record of Pharmakon Advisors, the fund enjoys access to its extensive, industry-focused knowledge and contacts to source, analyse and structure attractive investment opportunities. Through a shared services agreement with Royalty Pharma, founded in 1996, the Investment Manager will be able to rely on the complementary expertise of the team behind the market leading investor in pharmaceutical royalties. ~~~~~~~~~~~~~~~~~~~~ Significant Holdings (06 April 2017: Prudential .... 109,000,000 14.3% Phemus Corp .... 32,688,075. 4.3 Interseguro .... 27,200,000. 3.6 Adage C P ...... 25,284,247. 3.3 Jeremy Sillem* .... 300,000 Colin Bond* ....... 100,000 Duncan Budge* ..... 100,000 Harry Hyman* ...... 100,000 NAV values: 31/03/17 ... 98.04c 30/04/17 ... 98.36c 31/05/17 ... 98.66c
jonwig
Chat Pages: 1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170823 04:16:32